PharmHunterJen said:The useful move here is to separate what is established from what is widely repeated.
Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.
NurseAsh_DET said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
That reframing is the part I needed. I will report back once I have actually tried it.
PharmHunterJen said:The useful move here is to separate what is established from what is widely repeated.
Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.
I would rather be corrected than agreed with, if it comes to it.
Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.